High-throughput respirometric assay identifies predictive toxicophore of mitochondrial injury

Toxicology and Applied Pharmacology

Volumn 272, Issue 2, 2013, Pages 490-502

  Wills, Lauren P ^c   Beeson, Gyda C ^a   Trager, Richard E ^a   Lindsey, Christopher C ^a   Beeson, Craig C ^c   Peterson, Yuri K ^a   Schnellmann, Rick G ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^c MitoHealth Inc   (United States)

Author keywords

ChemBridge; LOPAC; Mitochondria; Renal proximal tubule cells; Seahorse Biosciences Extracellular Flux; Toxicophore

Indexed keywords

ENVIRONMENTAL CHEMICAL; TOXICOPHORE; TOXIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; EXERCISE TEST; FEMALE; HYPOTHESIS; KIDNEY PROXIMAL TUBULE; MITOCHONDRIAL TOXICITY; NONHUMAN; OXYGEN CONSUMPTION; PREDICTION; RESPIROMETRY; RISK ASSESSMENT;

CHEMBRIDGE; LOPAC; MITOCHONDRIA; RENAL PROXIMAL TUBULE CELLS; SEAHORSE BIOSCIENCES EXTRACELLULAR FLUX; TOXICOPHORE;

ANIMALS; CARBONYL CYANIDE P-TRIFLUOROMETHOXYPHENYLHYDRAZONE; CELL SURVIVAL; ENVIRONMENTAL POLLUTANTS; FEMALE; HIGH-THROUGHPUT SCREENING ASSAYS; KIDNEY TUBULES, PROXIMAL; MITOCHONDRIA; OXYGEN CONSUMPTION; PREDICTIVE VALUE OF TESTS; PRIMARY CELL CULTURE; PROTON IONOPHORES; RABBITS; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84884144226     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2013.06.014     Document Type: Article

References (44)

1. Arrington D.D., Van Vleet T.R., Schnellmann R.G. Calpain 10: a mitochondrial calpain and its role in calcium-induced mitochondrial dysfunction. Am. J. Physiol. Cell Physiol. 2006, 291:C1159-C1171. 10.1152/ajpcell.00207.2006.
2. Beeson C.C., Beeson G.C., Schnellmann R.G. A high-throughput respirometric assay for mitochondrial biogenesis and toxicity. Anal. Biochem. 2010, 404:75-81.
3. Birch-Machin M.A., Turnbull D.M. Methods in Cell Biology 2001, vol. 65:97-117. Academic Press, (Ch. 5). E.A. Schon, L.A. Pon (Eds.).
4. Bradbury S.P. Quantitative structure-activity relationships and ecological risk assessment: an overview of predictive aquatic toxicology research. Toxicol. Lett. 1995, 79:229-237.
5. Carlin R.W., Lee J.H., Marcus D.C., Schultz B.D. Adenosine stimulates anion secretion across cultured and native adult human vas deferens epithelia. Biol. Reprod. 2003, 68:1027-1034. 10.1095/biolreprod.102.009381.
6. Casalegno M., Sello G., Benfenati E. Top-priority fragment QSAR approach in predicting pesticide aquatic toxicity. Chem. Res. Toxicol. 2006, 19:1533-1539. 10.1021/tx0601814.
7. Chan K., Truong D., Shangari N., O'Brien P.J. Drug-induced mitochondrial toxicity. Expert Opin. Drug Metab. Toxicol. 2005, 1:655-669. 10.1517/17425255.1.4.655.
8. Chhabra R.S., Bucher J.R., Wolfe M., Portier C. Toxicity characterization of environmental chemicals by the US National Toxicology Program: an overview. Int. J. Hyg. Environ. Health 2003, 206:437-445.
9. Dykens J.A., Will Y. 91 Drug-induced mitochondrial toxicity: drug safety considerations. Mitochondrion 2007, 7:430-431.
10. Dykens J.A., Will Y. The significance of mitochondrial toxicity testing in drug development. Drug Discov. Today 2007, 12:777-785.
11. Dykens J.A., Marroquin L.D., Will Y. Strategies to reduce late-stage drug attrition due to mitochondrial toxicity. Expert. Rev. Mol. Diagn. 2007, 7:161-175. 10.1586/14737159.7.2.161.
12. Ferrick D.A., Neilson A., Beeson C. Advances in measuring cellular bioenergetics using extracellular flux. Drug Discov. Today 2008, 13:268-274.
13. Hirsch T., et al. Mitochondrial permeability transition in apoptosis and necrosis. Cell Biol. Toxicol. 1998, 14:141-145.
14. Huang R., et al. Weighted feature significance: a simple, interpretable model of compound toxicity based on the statistical enrichment of structural features. Toxicol. Sci. 2009, 112:385-393. 10.1093/toxsci/kfp231.
15. Hynes J., et al. Investigation of drug-induced mitochondrial toxicity using fluorescence-based oxygen-sensitive probes. Toxicol. Sci. 2006, 92:186-200. 10.1093/toxsci/kfj208.
16. Kaufmann P., et al. Toxicity of statins on rat skeletal muscle mitochondria. Cell. Mol. Life Sci. 2006, 63:2415-2425.
17. Kirkland D., et al. How to reduce false positive results when undertaking in vitro genotoxicity testing and thus avoid unnecessary follow-up animal tests: report of an ECVAM Workshop. Mutat. Res. Genet. Toxicol. Environ. Mutagen. 2007, 628:31-55.
18. Kortagere S., Ekins S. Troubleshooting computational methods in drug discovery. J. Pharmacol. Toxicol. Methods 2010, 61:67-75.
19. Labbe G., Pessayre D., Fromenty B. Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundam. Clin. Pharmacol. 2008, 22:335-353.
20. Lin H.-b, Cadete V.J.J., Sawicka J., Wozniak M., Sawicki G. Effect of the myosin light chain kinase inhibitor ML-7 on the proteome of hearts subjected to ischemia-reperfusion injury. J. Proteomics 2012, 75:5386-5395.
21. Marroquin L.D., Hynes J., Dykens J.A., Jamieson J.D., Will Y. Circumventing the Crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants. Toxicol. Sci. 2007, 97:539-547. 10.1093/toxsci/kfm052.
22. Nissim I., et al. 3-Isobutylmethylxanthine inhibits hepatic urea synthesis. J. Biol. Chem. 2008, 283:15063-15071. 10.1074/jbc.M800163200.
23. Nowak G., Schnellmann R.G. Improved culture conditions stimulate gluconeogenesis in primary cultures of renal proximal tubule cells. Am. J. Physiol. Cell Physiol. 1995, 268:C1053-C1061.
24. Nowak G., Schnellmann R.G. l-ascorbic acid regulates growth and metabolism of renal cells: improvements in cell culture. Am. J. Physiol. Cell Physiol. 1996, 271:C2072-C2080.
25. O'Brien P., et al. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch. Toxicol. 2006, 80:580-604.
26. O'Connor N.R. FDA boxed warnings: how to perscribe drugs safely. Am. Fam. Physician 2010, 81:298-303.
27. Peters-Golden M., Canetti C., Mancuso P., Coffey M.J. Leukotrienes: underappreciated mediators of innate immune responses. J. Immunol. 2005, 174:589-594.
28. Qian T., Herman B., Lemasters J.J. The mitochondrial permeability transition mediates both necrotic and apoptotic death of hepatocytes exposed to Br-A23187. Toxicol. Appl. Pharmacol. 1999, 154:117-125.
29. Rhoades J., et al. Prediction and in vitro evaluation of selected protease inhibitor antiviral drugs as inhibitors of carboxylesterase 1: a potential source of drug-drug interactions. Pharm. Res. 2012, 29:972-982. 10.1007/s11095-011-0637-9.
30. Rogers G.W., et al. High throughput microplate respiratory measurements using minimal quantities of isolated mitochondria. PLoS One 2011, 6:e21746.
31. Sakamuru S., et al. Application of a homogenous membrane potential assay to assess mitochondrial function. Physiol. Genomics 2012, 44:495-503. 10.1152/physiolgenomics.00161.2011.
32. Schnellmann R.G., Ewell F.P., Sgambati M., Mandel L.J. Mitochondrial toxicity of 2-bromohydroquinone in rabbit renal proximal tubules. Toxicol. Appl. Pharmacol. 1987, 90:420-426.
33. Schnellmann R.G., Cross T.J., Lock E.A. Pentachlorobutadienyl-cysteine uncouples oxidative phosphorylation by dissipating the proton gradient. Toxicol. Appl. Pharmacol. 1989, 100:498-505.
34. Servais H., et al. Renal cell apoptosis induced by nephrotoxic drugs: cellular and molecular mechanisms and potential approaches to modulation. Apoptosis 2008, 13:11-32.
35. Sherer T.B., et al. Mechanism of toxicity of pesticides acting at complex I: relevance to environmental etiologies of Parkinson's disease. J. Neurochem. 2007, 100:1469-1479.
36. Snyder S.H., Katims J.J., Annau Z., Bruns R.F., Daly J.W. Adenosine receptors and behavioral actions of methylxanthines. Proc. Natl. Acad. Sci. U. S. A. 1981, 78:3260-3264.
37. Tweats D.J., Scott A.D., Westmoreland C., Carmichael P.L. Determination of genetic toxicity and potential carcinogenicity in vitro-challenges post the Seventh Amendment to the European Cosmetics Directive. Mutagenesis 2007, 22:5-13. 10.1093/mutage/gel052.
38. Wallace K.B. Mitochondrial off targets of drug therapy. Trends Pharmacol. Sci. 2008, 29:361-366.
39. Wallace K.B., Starkov A.A. Mitochondrial targets of drug toxicity. Annu. Rev. Pharmacol. Toxicol. 2000, 40:353-388. 10.1146/annurev.pharmtox.40.1.353.
40. Weber B., Schlicker E., Sokoloff P., Stark H. Identification of the dopamine autoreceptor in the guinea-pig retina as D(2) receptor using novel subtype-selective antagonists. Br. J. Pharmacol. 2001, 133:1243-1248. 10.1038/sj.bjp.0704192.
41. Will Y., Hynes J., Ogurtsov V.I., Papkovsky D.B. Analysis of mitochondrial function using phosphorescent oxygen-sensitive probes. Nat. Protoc. 2007, 1:2563-2572.
42. Willett P. Similarity-based virtual screening using 2D fingerprints. Drug Discov. Today 2006, 11:1046-1053.
43. Xia M., et al. Compound cytotoxicity profiling using quantitative high-throughput screening. Environ. Health Perspect. 2007, 116.
44. Yokoi T. Handbook of Experimental Pharmacology: Adverse Drug Reactions 2010, vol. 196:419-435. Springer-Verlag, Berlin Heidelberg. J. Uetrecht (Ed.).